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ABSTRACT
Introduction There are no well-established criteria for
patients with corticobasal syndrome. The authors have
attempted to clarify this area by comparing and applying
three sets of well-known criteria (from Toronto, the
Mayo Clinic and Cambridge).
Patient and methods The authors first compared the
three criteria for overlap and differences, and then
applied them to a group of 40 consecutive patients (22
men, mean age 67 years) with focal cortical syndrome
characterised by apraxia and Parkinsonism, at both the
early stages and later in their illness.
Results Despite an overall similarity, there were major
differences in the criteria which affect their applicability.
Cognitive impairment was ubiquitous even at
presentation, with speech and language impairment the
commonest feature. Some classic features, alien limb
and myoclonus, were present in a minority only even late
in their course. The three criteria were equally applicable
to patients with advanced disease (Toronto 92.5%,
Cambridge 90% and Mayo 87.5%). Thirty patients (75%)
satisfied all three criteria. Using this group as a ‘gold
standard’, 73.3% fulfilled the Cambridge criteria at
presentation compared with 46.7% and 36.7% for the
Toronto and Mayo Clinic criteria, respectively.
Concordance between criteria was poor.
Conclusion Cognitive impairment, especially language
impairment, was prominent from onset of disease. The
Cambridge criteria apply to a higher proportion of cases
at an early stage of corticobasal syndrome. The authors
suggest a minor modification to capture the high
prevalence of aphasia.
INTRODUCTION
In the 40 years since its first description, cortico-
basal ganglionic degeneration (CBD) has become
a topic of considerable interest. Yet, despite many
reports, there are no agreed diagnostic criteria. As
first described, CBD was considered a primary
motor disorder characterised by asymmetrical
rigidity with apraxia and variable other features,
including cortical sensory loss, alien limb behaviour,
myoclonus and dystonia.1 Cognitive abilities were
stated to be relatively preserved.2 In fact, early
diagnostic criteria stated that early dementia was an
exclusion criterion.3 4 Subsequent studies, however,
described an increasing number of cases with
cognitive deficits, appearing early in the disease and
sometimes even before the onset of motor
symptoms.5e16 As a result, CBD is now regarded as
a complex disorder which affects motor and cogni-
tive function, although the relative importance of
these two major features remains controversial.
Neuropathologicaly patients with CBD were
reported to have disorder with tau-positive intra-
cellular inclusions, cortical ballooned neurons,
frontoparietal neuronal loss and gliosis, and nigral
and basal ganglia degeneration.9 More recently, it
has become clear that this classic picture is present
in a proportion of cases only, and many have other
pathologies, most notably Alzheimer ’s disease
(AD) and progressive supranuclear palsy.7 13 17e22
Moreover, the classic neuropathology of CBD is
found in patients who presented with progressive
aphasia or frontotemporal dementia, making it
difficult to maintain the term CBD as a unified
clinicopathological entity.12 14 23 24 This variability
in pathology has led a number of authors to
propose the label Corticobasal syndrome (CBS) for
the clinical syndrome.14
A major confound which presents difficulty in
the interpretation of the literature on CBS is
the lack of agreed and validated diagnostic criteria.
We surveyed current criteria; a number are poorly
specified or have been used to a limited
degree.4 25e27 Three sets of criteria are more clearly
defined: those proposed by Lang and Bergeron
(Toronto),3 Boeve et al (Mayo clinic),28 and Bak and
Hodges (Cambridge).13 29 In an attempt to ratio-
nalise clinical criteria, we compared these three sets
of criteria to examine areas of overlap and differ-
ences. We applied the three sets to a large group of
patients with a clinical diagnosis of CBS, where the
majority of the patients had focal cortical
syndrome, apraxia and extrapyramidal motor
features, seen in a clinic for patients with complex
movement disorders, to test their applicability and
relative performance, at both the early stages and
later in the course. Our final aim was to see if any
modifications to the criteria would better capture
the syndrome of CBS.
PATIENTS
We searched the database of the Disorders of
Movement and Cognition (DMC) Clinic, at
Addenbrooke’s Hospital, Cambridge for patients
who received a label of CBS. Of 69 potential cases,
40 had comprehensive records and had been
followed regularly. The DMC was established in
1997 as a tertiary multidisciplinary referral clinic for
patients with complex movement disorders. In
addition to the patients with CBS, the clinic also
assessed 276 with progressive supranuclear palsy, 22
with frontotemporal dementia with motor neuron
disease and 40 with multiple system atrophy.
Patients with a purely cognitive presentation were
assessed in the parallel Early Onset Dementia Clinic,
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also established in 1997. All patients were assessed by one of two
experienced neurologists (JRH and THB). All underwent neuro-
logical examination, neuroimaging (CT or MRI) and neuro-
psychological assessments, including the Addenbrooke’s
Cognitive Examination (ACE)30 31 and were followed up when-
ever possible until death. During neurological examination,
attention was paid to frontal executive functions, speech and
language, limb praxis, visuospatial processing, bradykinesia,
rigidity, involuntary movements and cortical sensory loss.
Histopathological diagnosis was available in 16 patients: six
patients had classic tau-positive CBD, eight Alzheimer ’s
dementia, one FTDeU and one a necrotising leucoencephalop-
athy. The details of several patients have been published.10 12 13 32
DATA COLLECTION
The clinical, neuroimaging information and neuropathology
results were reviewed by a neurologist (RM), who was not
involved with their diagnosis. The three selected clinical criteria
(Toronto, Mayo Clinic and Cambridge criteria) were applied. For
the purpose of this analysis, a feature was regarded as present if
it appeared at any stage in the clinical course. A feature, which
was not recorded, was considered as absent. Definitions of the
clinical features extracted are shown in box 1.
STATISTICS
Agreement between pairs of criteria was calculated with the use
of k statistics, which indicates the level of agreement, in which
0 reflects no agreement (ie, chance level) and 1 perfect agree-
ment. Fisher ’s exact test was used to calculate differences across
groups of patients. The statistics was calculated using SPSS V.18.
RESULTS
Comparison of three sets of criteria for the diagnosis of CBD
Table 1 compares the three criteria. The features common to all
criteria included extrapyramidal signs (rigidity, dystonia) and
cortical motor features (limb apraxia, alien limb phenomenon,
myoclonus and cortical sensory loss). There were, however,
significant differences. First, the Toronto criteria give no
importance to the temporal profile of illness, while others
include onset and progression of illness. Second, cognitive
features and extrapyramidal features are given equal weight in
the Cambridge criteria. The Mayo criteria include cognitive
dysfunction, but secondary to the movement disorder. The third
difference is the presence of exclusion features in the Toronto
criteria including progressive supranuclear palsy (vertical gaze
palsy), multiple system atrophy (severe autonomic disturbance),
idiopathic Parkinson’s disease (rest tremor, responsiveness to
levodopa), Alzheimer ’s dementia (early dementia) and structural
lesions (lesions on imaging). Fourth, none of the criteria specify
the stage at which given features are expected to be present, with
uncertainty, therefore, as to whether any given clinical mani-
festation is expected early or late, in the course of the disease.
In addition to these major differences, minor differences
across sets are present. Even the seemingly similar categories are
complicated by qualification terms. For example, rigidity, one of
the features common to all criteria, is described as simply
‘rigidity,’ ‘focal rigidity ’ and ‘akinetic rigid syndrome.’ Likewise
myoclonus is also described as ‘reflex focal myoclonus’ by two
criteria and by just ‘myoclonus’ by the Cambridge criteria. When
the categories are applied in the strict sense, only two features,
alien limb and cortical sensory loss, remain common to all the
three criteria. In our analysis, we combined features which are
clearly very similar (eg, myoclonus, rigidity).
Patient demographics
The male:female ratio was 22:18, and the mean age at presen-
tation was 67 years (SD 7.34). The mean duration of illness at
the time of presentation was 3 (SD 2.1) years, and the mean
duration of follow-up was 4.9 (SD 2) years. Death occurred at
a mean duration of 4.9 (SD 2.7) years from last visit.
Of the 40 patients, CBS was the primary diagnosis at their
first visit in 25 (62.5%). Three were diagnosed as having
Alzheimer ’s dementia, one with progressive supranuclear palsy,
one with frontotemporal dementia and one with progressive
non-fluent aphasia. CBS was the primary diagnosis of all the
cases by the time of their last visit.
Clinical features at initial presentation and on final assessment
All the patients had an insidious onset and gradual progression.
None of the patients showed a significant response to levodopa.
The commonest features were disturbance of speech and
language in 38 (95%) followed by limb apraxia 30 (75%).
Akinetic rigidity was present in 24 (60%). Of the 38 patients
with speech and language impairment, all were aphasic, of
Box 1 Definition of clinical features
< Asymmetry
– Asymmetry in motor features (rigidity, bradykinesia,
myoclonus or dystonia) or cortical sensory motor symp-
toms (apraxia, alien-limb syndrome or cortical sensory loss)
< Akinetic rigidity
– Rigidity and bradykinesia were both present
< Asymmetrical rigidity
– A difference of at least one grade across the sides when
the rigidity was graded according to a four-point scale
< Gait instability
– Postural instability on retropulsion test or gait apraxia
< Limb apraxia
– The inability to carry out learnt, skilled motor acts with
limbs despite preserved motor and sensory systems,
coordination, comprehension and cooperation, incorpo-
rating deficits copying meaningless gestures (limb kinetic)
or meaningful gestures to command (ideomotor); inability
to perform the Luria three-step test was not considered
significant evidence of apraxia
< Alien-limb syndrome
– Apparently purposeful actions of one hand against the
patient’s intention33
< Speech and language impairment
– The presence of a significant motor speech disorder with
distorted articulation or aphasia, typically non-fluent
< Frontal dysfunction
– Decreased verbal fluency, concreteness in thinking,
impaired reasoning, slowed information processing, lack
of insight, poor information retrieval, and impaired
execution of sequential actions. Personality changes may
include apathy, reflecting a lack of concern about personal
behaviour or the behaviour of others or disinhibition.34
< Frontal release signs
– At least one of the following was present: grasp, groping,
snout, pout, or palmo-mental reflex35
< Myoclonus
– Included reflex myoclonus, focal myoclonus, asymmetrical
myoclonus or reflex focal myoclonus.
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which the majority (60%) had a non-fluent syndrome, and most
of the remaining 40% were anomic. Less than half (17) also had
dysarthria. A sizeable number, 22 (55%), also had dysgraphia.
The various clinical features were divided into three broad
categories (see table 2). Cognitive impairment was seen in all
patients (100%) followed by cortical sensory motor symptoms
in 31 (77.5%) and primary motor symptoms in 27 (67.5%).
Cognitive involvement alone was present in three (7.5%). In 24
(60%), features from all the three domains were seen at their
first visit.
At the final visit to the clinic (see table 2) the commonest
features were still speech and language impairment seen in 38,
followed by apraxia 37 (92.5%) and frontal-lobe dysfunction 30
(75%). Myoclonus was present in almost half, and the alien-limb
phenomenon was seen in 40%.
Applicability of diagnostic criteria
At presentation to the clinic, the greatest number fulfilled the
Cambridge criteria (67.5%) followed by the Toronto (47.5%),
while the Mayo criteria (32.5%) were the least sensitive. The
difference between the former and the latter two was significant
(p¼0.005). Only 30% satisfied all three criteria, and 27.5% did
not qualify for any criteria on first visit. Overall, almost three-
quarters (72.5%) satisfied one of the three sets of criteria, while
almost half (47.5%) satisfied any of the two criteria. Of the
patients with histopathological diagnosis, five patients each
with CBD and AD were diagnosed by the Cambridge criteria on
first visit.
After the final visit, the proportion of patients fulfilling the
three criteria was very similar; Toronto 92.5%, Cambridge 90%
and Mayo 87.5%. Thirty patients (75%) satisfied all the three
diagnostic criteria, while all except one patient satisfied at least
two criteria. All six patients with histopathologically proven
tau-positive CBD as well as the eight patients with AD
pathology found their place in the group satisfying all the three
criteria. The patient with FTD-U, however, did not meet all the
three criteria.
Given the differences between the criteria, we took as a ‘gold
standard’ for clinical diagnosis the 30 patients who eventually
satisfied all three criteria and then examined the accuracy of
diagnosis at presentation. The Cambridge criteria diagnosed the
maximum number of patients on first visit (73.3%) followed by
the Toronto criteria (46.7%), while the Mayo criteria were the
least applicable (36.7%).
Table 1 Comparison of three criteria
Features Toronto criteria Mayo criteria Cambridge criteria
Temporal profile and treatment response
Insidious onset 0 1+ 0
Asymmetrical onset 0 0 1+
Chronic progressive course 0 1+ 0
Insidious onset and chronic progression 0 0 1
Levodopa-resistant 0 1 1
Sustained levodopa response Ex 0 0
Motor features
Rigidity 1 0 0
Focal rigidity 0 1 0
Asymmetrical rigidity 1 1 0
Akinetic rigid syndrome 0 0 1+
Dystonia 0 1 1
Focal dystonia 1 0 0
Myoclonus 0 0 1
Reflex focal myoclonus 1 1 0
Focal or asymmetrical myoclonus 0 1 0
Rest tremor Ex 0 0
Cortical sensory motor symptoms
Apraxia 1 0 1+
Asymmetric/focal apraxia 0 1 0
Number processing deficit 0 0 1
Cortical sensory loss 1 1 1
Alien limb 1 1 1
Visual or sensory hemineglect 0 1 0
Cognitive symptoms
Early dementia Ex 0 0
Frontal dysfunction 0 1 1+
Visuospatial deficit 0 0 1
Apraxia of speech/nonfluent aphasia 0 1 1
Exclusion features
Early vertical gaze palsy Ex 0 0
Severe autonomic disturbance Ex 0 0
Imaging of other pathology Ex 0 0
Imaging features 0 1* 0
No identifiable cause 0 1+ 0
0, not required or not relevant; 1, required; 1+, essential criteria in Mayo criteria and Cambridge criteria. In Cambridge criteria, three out of four essential criteria are needed for diagnosis.
1, supportive criteria; Ex, exclusion criteria.
*Mayo criteria include imaging features as supportive feature.
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Table 3 shows concordance and weighted k among various
criteria. Agreement was mild or poor between all pairs.
We explored any modifications of the Cambridge criteria that
would improve its applicability, replacing frontal executive
dysfunction with language impairment as a major criterion. The
modified Cambridge criteria are shown in box 2.
DISCUSSION
This is the first study to examine the utility of various criteria
for the diagnosis of CBS.3 25 We compared three well-known sets
of criteria and found that although they share key similarities,
there were important differences. When applied to a group of 40
patients, seen in a specialist clinic, there was poor concordance.
All three criteria could be applied equally well in the later stages,
but in the earlier stages the Cambridge criteria had significantly
wider applicability, almost certainly due to the weight given to
cognitive and language dysfunction.
The three clinical criteria chosen are all consensus criteria
derived on the basis of clinical experience by experts in the field,
rather than being derived from prospective natural history
studies with clinico-pathological correlation. The differences
reflect, therefore, differences in clinical experience and interest of
the teams involved, while there were clear similarities and
overlap, particularly in the need for an insidious onset and
progressive course (except in Toronto criteria) and the presence
of (usually) asymmetrical akinetic rigid syndrome with limb
apraxia. There were other key differences notably in the
emphasis on, or omission of, cognitive dysfunction from the
criteria. In the Toronto criteria, the presence of early dementia
was an exclusion criterion in sharp contrast to Cambridge
criteria where cognitive dysfunction formed one of the impor-
tant groups of diagnostic features.
Some motor features that are regarded as characteristic of
CBS, notably myoclonus and alien-limb phenomenon, were
present in less than a half of patients even when last seen in the
clinic, and were considerably rarer at presentation. These
features may have been overemphasised in description of CBS
and feature too prominently in some criteriadfor example,
Toronto criteria.
It is notable that all 40 patients in our study had some form of
cognitive impairment, even at the time of presentation, manifest
as language impairment, memory loss or frontal-lobe dysfunc-
tion. It is now generally accepted that cognitive impairment is
common in CBS; however, the exact prevalence remains
unknown, as the vast majority of studies have been based on
a small number of patients. Also, the interpretation of the
available estimates is hampered by methodological issues.11 Prior
studies have shown that impairment of frontal-lobe function
was one of the most consistent cognitive abnormalities. It has
been estimated that executive dysfunction with behavioural
disturbance or poor performance on frontal-lobe tests is present
in at least 50% of the patients with CBD.15 Dubois and
colleagues showed that a group of 21 patients were all impaired
on frontal-lobe function.36 Our study, in keeping with Dubois
et al, found a large number of patients with cognitive impair-
ment at presentation.
One striking observation was the prominence of speech and
language abnormalities, which were present in the vast majority
of patients, even at their first assessment. A similar observation
was made by Graham et al10 in a smaller study, which found
that the majority of their patients had evidence of aphasia, but
this was typically subclinical and apparent only after detailed
testing of speech and language function. Moreover, all the
Table 2 Percentage of patients having various manifestations at
presentation and final visit
First visit-no of
patients (%)
Final visit- no of
patients (%)
Motor features 27 (67.5) 39 (97.5)
Akinetic rigidity 24 (60) 29 (72.5)
Gait instability 15 (37.5) 25 (62.5)
Myoclonus 12 (30) 18 (45)
Cortical motor sensory features 31 (77.5) 37 (92.5)
Limb apraxia 30 (75) 37 (92.5)
Alien-limb syndrome 11 (27.5) 16 (40)
Cortical sensory loss 08 (20) 18 (45)
Cognitive features 40 (100) 40 (100)
Speech and language 38 (95) 38 (95)
Frontal dysfunction 23 (57.5) 30 (75)
Visuospatial deficits 19 (47.5) 22 (55)
Frontal release signs 13 (32.5) 24 (60)
Table 3 Concordance and k values between various criteria
Criteria Percentage concordance k values
Mayo and Cambridge 82 0.125
Mayo and Toronto 84 0.172
Cambridge and Toronto 87 0.219
Box 2 Modified Bak and Hodges criteria
(Cambridge criteria){
< Mandatory criteria
– Insidious onset and gradual progression
– No sustained response to levodopa treatmenty
< Major and minor criteria*
– Motor features
Akinetic rigid syndrome
Focal or segmental myoclonus
Asymmetrical dystonia
– Cortical motor sensory features
Limb apraxia
Alien limb phenomenon
Cortical sensory loss or dyscalculia
– Cognitive features
Speech and language impairmentz
Frontal executive dysfunctionx
Visuospatial deficits
*Criteria in italics are major criteria, and the rest are minor
criteria.
yThe response of the parkinsonism to levodopa therapy should
be tested with at least 25/250 mg of carbidopa/levodopa
administered three times a day for at least 2 months. The
response to levodopa is considered poor when the extrapyra-
midal features fail to show marked improvement, or the thera-
peutic effect is transient (ie, lasts less than a year).34
zIncludes aphasia, dysarthria and dysgraphia.
xIncludes frontal release signs reduced verbal fluency and other
abnormal tests of frontal functions.
{For a diagnosis of CBS, the patient should satisfy all mandatory
criteria, two major criteria (in italics) and two minor criteria.
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patients in the Graham et al study had limb apraxia or extra-
pyramidal symptoms at the time of presentation. Their review
of the literature revealed that over a third of reported CBS cases
had clinically obvious aphasia most often of the non-fluent
type.10 Murray et al also reported language dysfunction to be the
most commonly reported complaint early in the CBD with
word-finding difficulty, effortful speech or dysgraphia.37 The
present study goes further. Nearly all patients had speech and
language impairment at presentation that was characterised as
non-fluent in type. Apraxia of speech has been associated with
underlying s pathology.38e40 Unfortunately, we are not able to
say what proportion of our patients had apraxia of speech since
a detailed perceptual analysis of speech samples was not avail-
able. This finding adds to the growing awareness of the clinical
overlap between CBS and progressive non-fluent aphasia.14
The main reason for the difference between the Cambridge,
Toronto and Mayo criteria is the equal emphasis in the
Cambridge criteria on motor and cognitive features together
with their use of major versus minor criteria. We have suggested
a slight modification while keeping the basic structure whereby
frontal executive dysfunction, which was a major criterion, was
replaced by speech and language impairment. For better speci-
ficity, some of the criteria (insidious onset and gradual progres-
sion, and levodopa insensitivity) were made mandatory.
Diagnostic criteria for any disorder should ideally be validated
against an independent biological ‘gold standard.’ Unfortunately,
the variable pathology in CBS presents insuperable problems in
this regard. As highlighted in the introduction, a proportion of
patients have classic s-positive intracellular inclusions with
cortical ballooned neurons,9 but a considerable minority have
other pathologies, most notably AD.7 13 18e21 As a surrogate for
this ideal validation, we took the subgroup of patients who
fulfilled all of three established diagnostic criteria comprising 30
(75%) of the 40 cases. All six patients with histopathological
proven tau-positive CBD were included in this core group as well
as the eight patients with AD. It has previously been suggested
that a number of clinical features, notably early memory
complaints and deficits on the ACE, and a lack of behavioural
changes are indicative of AD pathology, but we were unable to
support or refute this prior finding.13
The large number of patients in this cohort with cognitive
features at presentation raises the issues related to referral bias.
Even though such a possibility cannot be ruled out totally, the
influence of such a bias is likely to be low. The DMC clinic was
established to evaluate patients with disorders of movement and
cognition. Thus, virtually all patients had motor features, even if
these were not predominant. Only three patients had cognitive
features alone at presentation. A parallel clinic in Cambridge was
established in 1997 in which large numbers of patients with pure
cognitive disorders were assessed. We would argue that the high
rate of language and cognitive dysfunction reflects, instead, the
interest and expertise of the two senior neurologists (TB and
JRH) who evaluated all of the patients and the use of
a systematic evaluation tools designed to uncover and classify
disorders of cognition which is not the situation in most
movement disorder clinics.
In conclusion, the available clinical criteria for CBS differ
considerably. All three apply equally well to patients in the
advanced stages of the disorder, but at presentation the
Cambridge criteria appear to capture a higher proportion of cases
because of their more structured nature and their emphasis on
cognitive dysfunction. Although the number of cases with post-
mortem pathology is relatively small, there were no major
differences between those with classic CBD and those with
AD.14 Prospective longitudinal studies with clinico-pathological
correlation are clearly required.
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